Sirnaomics Initiates Phase 2 Study Using STP705 for Keloid Scar Prevention prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Sirnaomics to Present at Medical Dermatology Summit
News provided by
Share this article
, a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced that it will be presenting results from a recently completed Phase 2a clinical study of the company s lead drug candidate, STP705, for treatment of squamous cell skin cancer, at the 19th Annual South Beach Symposium Medical Dermatology Summit. The virtual conference runs from Feb. 5-7, 2021.
Title: Innovation in the Treatment of NMSC: siRNA STP705 for SCC in situ
Presented by: Mark Steven Nestor, M.D., Ph.D.; Director, Center for Cosmetic Enhancement, Center for Clinical and Cosmetic Research in Aventura, Florida
Search jobs 20-Dec-2020 Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced positive efficacy and safety results from a Phase 2a clinical study of the company s lead drug candidate, STP705, for treatment of squamous cell skin cancer.
The open label, dose escalation study was designed to evaluate the efficacy and safety of intralesional injection of STP705 in adult patients with cutaneous squamous cell carcinoma in situ (isSCC, Bowen s disease), confirmed with biopsy samples. The objective was to determine the safe and effective recommended dose of STP705 for the treatment of isSCC, as well as to analyze biomarkers common to isSCC formation pathways
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Sirnaomics Reports Positive Data from Phase 2a Study of STP705 for Treatment of Squamous Cell Skin Cancer
December 20, 2020 GMT
Sirnaomics Company Logo (PRNewsfoto/Sirnaomics, Inc.)
GAITHERSBURG, Md. and SUZHOU BIOBAY, China, Dec. 20, 2020 /PRNewswire/ Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced positive efficacy and safety results from a Phase 2a clinical study of the company’s lead drug candidate, STP705, for treatment of squamous cell skin cancer.
The open label, dose escalation study was designed to evaluate the efficacy and safety of intralesional injection of STP705 in adult patients with cutaneous squamous cell carcinoma in situ (isSCC, Bowen’s disease), confirmed with biopsy samples. The objective was to determine the safe and effective recommended dose of S